Company
Every investor coverage indicates participated in a round THRUST Strategic Communications raised.
Companies THRUST Strategic Communications acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming THRUST Strategic Communications. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.